Tibsovo Approval Expanded for Newly Diagnosed IDH1-Mutated AML
The approval was based on data from the phase 3 AGILE trial.
Acute Myeloid Leukemia
Adding Pevonedistat to Azacitidine Does Not Improve Outcomes for Patients With MDS/CMML and AML
Researchers sought to determine whether adding pevonedistat to azacitidine would improve outcomes for patients with higher-risk MDS, CMML, or AML.
Guadecitabine Is Not Superior to Treatment Choice in Patients With Pretreated Acute Myeloid Leukemia
Researchers sought to determine whether guadecitabine would have an overall survival benefit for patients with relapsed/refractory acute myeloid leukemia.
Treatment With Azacitidine, Lenalidomide and Donor Lymphocyte Infusion in Myeloid Malignancies After Relapse Following Allo-SCT
Patients received up to 8 cycles of AZA and up to 3 cycle of DLI with increasing T cell dosages.
Anti-CLL1 CAR T Cells Produce Responses in Pediatric Acute Myeloid Leukemia
Eight patients had a complete response within 1 month of infusion.
Patients With Acute Myeloid Leukemia May Have Suboptimal Outcomes Because of Fears of Treatment Side Effects
Researchers sought to determine whether patients with AML were being undertreated due to patient fear about side effects to treatment.
Aspacytarabine Is Safe, Effective in First-Line Acute Myeloid Leukemia
Researchers sought to determine whether first-line aspacytarabine would be safe and effective in patients with AML who cannot tolerate chemotherapy.
Poor COVID-19 Outcomes Among Patients With Hematologic Malignancies: Results From ECOVIDEHE
Patients with AML or MDS were significantly more likely to die from COVID-19 vs other HMs. Most treatments did not improve survival outcomes — except corticosteroids.
Gilteritinib-Azacitidine Tested in R/R FLT3-Mutated AML
Now that the phase 2 dose is established, a randomization cohort will test the efficacy of the treatments in the LACEWING trial.
Disadvantaged Neighborhood Status Increased Risk for Death From AML
Census tract affluence, disadvantage, and segregation were all significant predictors of leukemia-related death.
